2022年6月5日

分享我的智能机器(mim)——的领导者利用系统生物学,生物信息学,人工智能推出一个产品将改变公司在肿瘤临床试验准备。使用一个复杂的系统生物学和机器学习平台专门为他们建造的,生命科学家现在能够预测反应好的新疗法多轻松更高的性能比其他可用的方法。此外,他们可以在一天内完成一个月的工作,成果在十分之一的生物信息学和数据科学咨询服务的成本。mim项目的软件解决方案在肿瘤患者使用表达式的数据从16000年200多个癌症类型和能够提供关键的见解药物的作用机制和药物协同作用在个别病人的上下文中。“作为一名生物学家,我总是梦想成为更多的自治在我的研究中涉及下一代测序;探索我的想法和见解的能力没有成本,时间,和依赖他人来帮助我处理和分析自己的数据,”莎拉说詹娜,mim项目的联合创始人兼首席执行官。“mim项目,生命科学家现在可以独立地利用系统生物学,人工智能,和自己的深刻的人类知识和经验在癌症生物学推动创新和药物发现的边界。“mim肿瘤研究产品提供科学见解支持战略决策指示优先级处于临床前阶段。它使研究人员能够增加II和III期临床试验的成功率;探索新的有效的综合治疗;早期,加快高附加值的生物标志物来加速同伴测试开发。 Related Posts MIMs’ platform integrates the company’s MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, multi-omic and clinical patient data—and MIMs’ proprietary GI2 algorithm, which infers genetic interactions within patient tumors and immune systems. The platform creates vivid human cartographies of individual patients, which deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers. Jenna continues, laughing. “Six years ago, when we explained to people what we were building our platform to do, they called it science fiction! Today, these same people are buying annual licenses.” My Intelligent Machines will be in Chicago this week, at the American Society of Clinical Oncology (ASCO) Meeting and invites people to stop by Booth IH20 to learn more about this exciting new approach. To celebrate the product launch, and being back at ASCO in-person, MIMs is offering special promotional pricing, with a 30-percent discount on its Lite and Plus SaaS platform packages. The company also encourages those interested in a free 30-day trial to contact them directly.